Athenex Inc (ATNX) Gross Profit Margin starting from the fourth quarter 2022 to fourth quarter 2021, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Athenex Inc   (NASDAQ: ATNX)


Athenex Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ATNX Gross Profit Margin (Dec 31 2022)
Q4 		(Sep 30 2022)
Q3 		(Jun 30 2022)
Q2 		(Mar 31 2022)
Q1 		(Dec 31 2021)
Q4
Y / Y Revenue Change -67.71 %
Seq. Revenue Change -75.99 %
Revenue In Millions $8.05
Gross Profit Margin 75.22 %
Gross Profit Margin Total Ranking # 803
Gross Profit In Millions $6.06
Y / Y Gross Profit Change 42.76 %
Seq. Gross Profit Change 4.52 %


Commenting fourth quarter 2022 Gross Profit Margin
Athenex Inc achieved Gross Profit of $6 millions compare to Gross Loss of $5.79 millions booked in the previous quarter. Despite the sequential Revenue deterioration in Q4 of -75.99 % Athenex Inc managed to reduce Cost of Sales and increase Gross Profit by 4.52 % to $6 millions. Gross Profit Margin grew to 75.22 % a new company high.


Observing fourth quarter 2022 results within Major Pharmaceutical Preparations industry 82 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 803, from total ranking in the previous quarter at 3369.
Learn about Gross Margin
ATNX's Gross Profit Margin fourth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 83
Healthcare Sector # 150
Overall # 786

Gross Profit Margin Statistics
High Average Low
75.22 % 31.45 % 9.97 %
(Dec 31 2022)   (Jun 30 2017)


ATNX Gross Income Trends • More of ATNX's Profitabilty Ratios • ATNX Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
ATNX's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
ATNX's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for ATNX's Competitors
Gross Profit Margin Profit Margin for Athenex Inc 's Suppliers
Gross Profit Margin Profit Margin for ATNX's Customers

You may also want to know
ATNX's Annual Growth Rates ATNX's Profitability Ratios ATNX's Asset Turnover Ratio ATNX's Dividend Growth
ATNX's Roe ATNX's Valuation Ratios ATNX's Financial Strength Ratios ATNX's Gross Profit Growth
ATNX's Roa ATNX's Inventory Turnover Ratio ATNX's Growth Rates ATNX's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Gross Profit MarginDec 31 2022 MRQ Gross ProfitDec 31 2022 MRQ Revenue
Immuneering Corporation  100.00 %$ 0.000  Millions$ 0.000  Millions
Macrogenics Inc   99.84 %$ 72.983  Millions$ 73.099  Millions
Ptc Therapeutics inc   99.70 %$ 166.913  Millions$ 167.413  Millions
Uniqure N v   99.57 %$ 102.306  Millions$ 102.745  Millions
Pasithea Therapeutics Corp   99.46 %$ 0.239  Millions$ 0.241  Millions
Rigel Pharmaceuticals Inc  99.33 %$ 50.936  Millions$ 51.278  Millions
2seventy Bio Inc   99.16 %$ 55.703  Millions$ 56.177  Millions
Cormedix Inc   98.63 %$ 0.029  Millions$ 0.030  Millions
Corcept Therapeutics Inc  98.56 %$ 101.576  Millions$ 103.056  Millions
Acadia Pharmaceuticals Inc   98.23 %$ 134.076  Millions$ 136.490  Millions
Calliditas Therapeutics Ab  98.11 %$ 84.675  Millions$ 86.309  Millions
Adc Therapeutics Sa  97.82 %$ 205.329  Millions$ 209.908  Millions
Galapagos Nv  97.61 %$ 552.385  Millions$ 565.914  Millions
Ionis Pharmaceuticals Inc   97.57 %$ 148.204  Millions$ 151.890  Millions
Travere Therapeutics Inc   96.91 %$ 54.140  Millions$ 55.868  Millions
Bioxcel Therapeutics Inc   96.22 %$ 0.229  Millions$ 0.238  Millions
Whitehawk Therapeutics Inc   95.75 %$ 5.005  Millions$ 5.227  Millions
Ligand Pharmaceuticals Incorporated  95.50 %$ 25.827  Millions$ 27.045  Millions
Aurinia Pharmaceuticals Inc   95.21 %$ 27.073  Millions$ 28.435  Millions
Sage Therapeutics Inc   95.01 %$ 2.721  Millions$ 2.864  Millions
Ultragenyx Pharmaceutical Inc   94.85 %$ 98.029  Millions$ 103.348  Millions
Xbiotech Inc   94.67 %$ 0.284  Millions$ 0.300  Millions
Cti Biopharma Corp   94.46 %$ 19.916  Millions$ 21.083  Millions
Quantum Cyber N v   94.24 %$ 0.182  Millions$ 0.193  Millions
Y mabs Therapeutics inc   93.57 %$ 29.426  Millions$ 31.447  Millions
Zevra Therapeutics Inc   93.49 %$ 2.168  Millions$ 2.319  Millions
Ardelyx inc   92.84 %$ 41.016  Millions$ 44.178  Millions
Ocular Therapeutix Inc   92.81 %$ 13.064  Millions$ 14.076  Millions
Myovant Sciences Ltd   92.60 %$ 92.811  Millions$ 100.229  Millions
Bellicum Pharmaceuticals Inc   92.40 %$ 0.462  Millions$ 0.500  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.